Faron Pharmaceuticals Ltd on Wednesday said data from its phase 1 BEXMAB study has shown positive data.
The Finland-based clinical-stage biopharmaceutical company said three of five patients in the bexmarilimab with azacitidine doublet cohort met the obtrial’s objective responses. Overall, eight out of 15 objective responses were seen in all three cohorts.
The firm said one patient also achieved a full blood count recovery.
Bexmarilimab is an immunotherapy designed to overcome resistance to existing treatments for acute myeloid leukaemia, a type of cancer, and myelodysplastic syndromes.
The firm noted that one patient has stayed on the treatment for 15 months.
Faron said the data supports the advancement of the trial to phase 2 in the second half of 2023, with its first biologics license application to the US Food & Drug Administration planned for the first half of 2025.
Chief Medical Officer Marie-Louise Fjallskog said: ‘The data indicates bexmarilimab has the strong potential to tackle an unmet medical need in relapsed/refractory AML and MDS. We’re excited to advance bexmarilimab as a leading agent in the fight against cancer and look forward to generating further supporting data ahead of an anticipated BLA filing in H1 2025.’
Faron shares rose 5.9% to 268.00 pence each on Wednesday morning in London.
Copyright 2023 Alliance News Ltd. All Rights Reserved.
